Durata Therapeutics, Inc. Presenting Two Abstracts Concerning Dalbavancin at IDWeek 2012

MORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that data from two clinical trials of its lead product candidate, dalbavancin, will be presented in two posters during the IDWeek conference in San Diego from October 17-21, 2012. IDWeek is the first-ever combined meeting of four prestigious societies: the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS).